Non-Hodgkin lymphoma (NHL) comprises a large diverse group of malignant neoplasms that are derived from cells of the immune system. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms recognizes more than 60 different types of lymphoma.
Epidemiology
Non-Hodgkin lymphoma (NHL) comprises a large diverse group of malignant neoplasms that are derived from cells of the immune system. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms recognizes more than 60 different types of lymphoma.
1 While a majority of NHLs present with adenopathy, primary extranodal lymphomas account for 10 to 34% of all cases.
2
Although the gastrointestinal (GI) tract is not commonly considered a lymphoid organ, the gut-associated lymphoid tissues contain the largest number of lymphocytes in the body. The GI tract is the most common site for extranodal lymphoma and accounts for 30 to 40% of all cases. 3, 4 Primary lymphoma of the colon and rectum is the least common GI location, and accounts for 10% of GI lymphomas and < 1% of all large bowel malignancies. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Distribution of the six most common subtypes of GI lymphoma, based on the two largest GI lymphoma studies, is represented in ►Table 1.
12,13
Incidence of colorectal lymphoma is highest between the ages of 50 and 70 years, and is predominantly male, with an approximate ratio of 2:1.
12,15-18
Although rare, lymphoma of the colon and rectum presents unique management challenges, stemming primarily from the high risk of radiation to the bowel in contrast to nodal beds elsewhere in the body. Thus, in early-stage disease, definitive local control relies more commonly on surgical resection that is otherwise rarely used for treatment of lymphoma. Given the limited data to guide decisions, the best approach to the management of localized disease can be challenging, and we suggest a multidisciplinary approach with early involvement of surgical oncology, gastroenterology, radiation oncology, and malignant hematology.
In this article, we review the epidemiology, clinical presentation, diagnosis, pathology, and staging of primary colorectal lymphoma. We outline the evidence and suggest approach to management of several of the most common histologic subtypes of primary colorectal lymphoma.
Risk Factors
Etiology and risk factors, specifically for primary colorectal lymphoma, remain largely unknown. It is reasonable to suspect that established risk factors for NHL will also increase risk for primary colorectal lymphoma. These risk factors include a family history of lymphoma, past radiation or chemotherapy treatment, immunosuppressive medications, organ transplantation, viral infections (e.g., human immunodeficiency virus, hepatitis C virus, human T-cell leukemia virus 1, Epstein-Barr's virus, and hepatitis B virus), and toxic exposures (e.g., agricultural pesticides and Agent Orange). [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] In addition, several medical conditions are associated with an increased risk of NHL, including autoimmune disorders, immunodeficiency disorders, mixed cryoglobulinemia, multicentric Castleman's disease, and obesity. [30] [31] [32] [33] [34] Colitis from inflammatory bowel disease has not been shown to increase risk of lymphoma; immunosuppression with azathioprine or mercaptopurine, however, has been associated with an increased risk of GI lymphoma.
Clinical Presentation
Presenting symptoms may include weight loss, fevers, night sweats, and lethargy, as well as symptoms of colorectal anatomical compromise, including palpable abdominal mass, occult or apparent GI bleeding, diarrhea, abdominal pain, intussusception, or bowel obstruction. Histologic diagnosis is usually obtained upon pathologic examination of endoscopic or surgically resected tissue. Findings on endoscopic examination are varied and include mucosal nodularity, mucosal induration, mucosal ulceration, and mass with or without ulceration. 45 Follicular lymphoma typically has no erosions or ulcers, and can often be macroscopically observed as papular, polypoid, or flat elevated lesions.
46
T cell lymphomas are more commonly associated with ulcerative lesions and perforation than B cell lymphomas.
39
Imaging with endoscopic ultrasound and computed tomography may demonstrate ulcerative or nodular patterns on imaging.
47 Double-contrasted barium enema may reveal various findings, including polypoid masses, circumferential infiltrative mass (with or without ulceration), cavitary masses, mucosal nodularity, and fold thickening. 48 More rarely, focal strictures, aneurysmal dilatation, and ulcerative forms with fistula formation may also be seen. Lymphoma is more likely than adenocarcinoma to show extension into the terminal ileum, have well-defined margins, preservation of fat planes, an absence of invasion into adjacent structures, and perforation with no desmoplastic reaction. 48 Ultimately, diagnosis is based on histologic, flow cytometric, and molecular evaluation of an adequate tissue specimen. This may require multiple needle biopsies, partial resection, or complete resection. Fine needle aspiration is usually inadequate to determine the specific lymphoma subtype.
Pathologic Classification
The vast majority of GI lymphomas, including colorectal lymphomas, are NHLs. There are only a few case reports of primary GI Hodgkin lymphoma. 
Surgical Management
The role of surgery in the initial management of colorectal lymphoma has been a matter of historical debate. Patients with colonic lymphoma do not uncommonly present with acute surgical indications, including bleeding, obstruction, or perforation, necessitating upfront surgical resection. 51 A first paradigm in surgical intervention for local disease has been advocated for with the argument that it may, in larger lesions, decrease rates of perforation and bleeding that can be seen when chemotherapy is initially used. It may also increase longterm remission rates over chemotherapy alone.
63
In a large retrospective analysis that included 345 patients with intestinal DLBCL, patients with limited-stage I/II disease and surgery plus chemotherapy demonstrated a lower recurrence rate of 15.3%, when compared with chemotherapy alone, at 36.8%, with an improved 3-year overall survival (OS) rate of 91%, compared with 62% with chemotherapy alone. 64 In addition, a prospective nonrandomized trial that included 40 patients with stage I/II GI DLBCL (44% large bowel) who received primary surgical resection followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy demonstrated favorable outcomes with a 5-year disease-free survival rate of 83%. 65 Unfortunately, there are no randomized comparative studies between the two approaches to better determine the optimal treatment approach.
Diffuse Large B Cell Lymphoma
DLBCL is the most common nodal lymphoma histology found in colonic lymphoma. High (>80%) long-term remission rates can be obtained in nonbulky (< 7.5 cm), limited-stage, nodal DLBCL treated with either abbreviated (three cycles) or full (six cycles)-course systemic, multiagent immunochemotherapy with rituximab-CHOP (R-CHOP) plus or minus involvedsite radiation therapy (RT).
66-69
In contrast to nodal lymphoma, treatment of localized colorectal DLBCL includes consideration for surgical resection, due to riskof both acute and chronic radiotherapy-induced gut toxicity. The efficacy of surgical resection followed by chemotherapy has Colorectal Lymphoma Gay et al. 311
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been assessed in several retrospective and one prospective analysis with high (>80%) 3-year disease-free survival rates, and was superior to immunochemotherapy alone.
64,65,70,71
For unresectable DLBCL of the colon or rectum, treatment with a full six cycles of an R-CHOP-like regimen is generally used. In nodal lymphoma, radiation is considered for incomplete positron emission tomography (PET) response after completion of upfront systemic chemotherapy for bulky disease. Adjuvant/consolidative involved field or involved site RT can be considered in primary colorectal lymphoma; risks associated with bowel radiation, however, often preclude treatment (►Fig. 1).
72

Follicular Lymphoma
Follicular lymphoma is one of the more common primary colorectal lymphoma subtypes. In nodal follicular lymphoma, patients with localized low-grade (grades 1-3a) disease are candidates for curative mono-or multimodality therapy, as opposed to advanced disease which is considered incurable, and is generally managed with palliative systemic therapy plus or minus RT. Patients with grade 3b follicular lymphoma are treated as aggressive lymphoma and are generally considered curable. 73, 74 Comprehensive staging with PET scan and bone marrow biopsy should be obtained to assess for more advanced disease, as this would dramatically change management from aggressive upfront local therapy with surgery or radiation plus or minus chemoimmunotherapy to a palliative-only approach, which often only managed with upfront observation. Long-term disease-free survival can be obtained in primary colorectal follicular lymphoma with aggressive upfront local therapy. 75 Given the complexities of assessing risk and feasibility of upfront colorectal radiation or surgery, we suggest multidisciplinary evaluation of all patients with early-stage primary colorectal follicular lymphoma. Large bowel radiation sensitivity and risk of long-term complications from RT makes surgical resection an attractive upfront treatment of choice. Adjuvant immunochemotherapy in the treatment of primary colorectal follicular lymphoma is of unclear additional benefit. There are single case reports and series that report long-term disease-free survival with surgery with or without adjuvant chemoimmunotherapy. 75 Adjuvant immunochemotherapy will reduce any postsurgical residual disease, but it is unlikely to completely eliminate it. If there are negative margins upon surgical resection, we suggest clinical monitoring only. If there is residual disease after resection, local RT can be considered in an attempt to establish cure; given the indolent nature of most follicular lymphoma, however, observation would also often be appropriate (►Fig. 2). Initial treatment with immunochemotherapy can result in good disease control and long periods of asymptomatic disease, and would be a reasonable treatment option for patients who have contraindication for surgery or radiation, or where disease control is an appropriate treatment goal.
Colorectal Mantle Lymphoma
Limited-stage mantle cell lymphoma (MCL) is rare, and the optimal treatment algorithm is not clear. In one retrospective analysis that included 26 patients with stages IA to IIA nodal disease, 65% of patients were managed with involved field radiation with or without chemotherapy. The other 35% were treated with observation alone. The 5-year progression-free survival (PFS) was 65% in the intervention group, and 46% in the observation group, and OS was 86 and 70%, respectively. 76 PFS was statistically and significantly improved when RT was included, compared with not, with a trend toward improved OS. In a more recent and larger retrospective study that included 2,539 patients with stages I to II MCL, estimated 3-year OS for patients receiving chemotherapy, RT, or chemotherapy plus RT were 67.8, 72.4, and 79.8%, respectively, which was statistically significant, and appeared to support the idea that combined therapy may improve survival.
77
Extrapolating these data from patients with early-stage nodal MCL to patients with primary colorectal MCL, we again confront the issue of both short-and long-term toxicities of bowel irradiation. If limited-stage disease involves an area of the colon that cannot be safely irradiated, we suggest upfront surgical resection, with adjuvant RT plus or minus chemoimmunotherapy, depending on surgical margins (►Fig. 3).
Mucosa-Associated Lymphoid Tissue
GI MALT lymphoma most commonly occurs in the stomach and small intestine but can occur in the colon and rectum (< 1% of cases). 78, 79 Common clinical presentations include rectal bleeding, iron deficiency, and incidental discovery on screening endoscopy. Endoscopically, large bowel MALT lymphomas can have a variety of appearances, but are usually elevated polypoid or submucosal tumor-like lesions that rarely have ulceration, as opposed to gastric MALT, which more frequently shows ulceration. Helicobacter pylori infection is less common in rectal MALT lymphoma, occurring in only the minority of cases, when compared with gastric MALT lymphoma, where it contributes to 90% of cases. In addition, eradication of H. pylori does not have the clear efficacy in rectal MALT lymphoma that it does in the stomach. In one study, antimicrobial irradiation showed a response in only 1 out of 15 cases.
80,81
Pathology of colorectal MALT lymphoma is characterized by infiltration of centrocyte-like cells with immunohistochemistry, demonstrating expression of CD19, CD20, and CD79 without expression of CD5, CD10, CD23, and cyclin D1.
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There is a paucity of data on ideal management of colorectal MALT lymphoma. There are case reports describing successful treatment of colorectal lymphoma with radiation only, surgical resection, or endoscopic mucosal resection.
80,83-85
Management of localized lesions depends on depths and size of lesion. Small, shallow lesions may be amenable to endoscopic submucosal resection. Deeper and larger lesions typically require surgery and/or RT. Adjuvant systemic chemoimmunotherapy can be considered if the setting or positive margins are not amenable to RT.
Disseminated MALT lymphoma is treated primarily with chemotherapy. Successful use of a variety of regimens, including alkylators, purine analogs, and anthracyclines has been demonstrated. 86 
Summary/Conclusion
Colorectal lymphoma is rare and pathologically heterogeneous. Both high-grade and low-grade lymphomas can occur with NHL subtypes of DLBCL, follicular, mantle, with MALT lymphomas being the most common. Appropriate staging with PET/CT scan and bone marrow biopsy is critical to assure accurate stage and confirm localized disease. For all subtypes that present with localized disease, a multidisciplinary approach should be undertaken, as surgical resection and RT with or without systemic chemoimmunotherapy may be appropriate, and result in long-term disease-free survival. This stands in contrast to advance NHL, which is primarily treated with systemic chemoimmunotherapy. 
